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Summary Expenrmental studies have been carried out using 5-aminolaevulinic acid (ALA) to induce transient porphyrin photosensitisation for photodynamic therapy (PDT) in a pancreatic cancer model in Syrian golden hamsters. ALA was given either intravenously or orally (in bolus or fractionated doses) with the laser light delivered by means of a bare fibre touching the tissue surface or external irradiation using a light-integrating cylindrical applicator. Animals were killed 1-24 h after ALA administration for pharnacokinetic studies and 3-7 days after light exposure to study PDT-induced necrosis. A separate survival study was also performed after a fractionated oral dose of ALA and external irradiation. Protoporphyrin IX sensitisation in the tumour tissue as measured by quantitative fluorescence microscopy was highest after intravenous administration of 200 mg kg-' ALA and then in decreasing order after oral fractionated and oral bolus doses (both 400 mg kg-'). Laser light application at 630 nm to give 12-50 J from the bare fibre or 50 J cm-2 using surface illumination with the cylindrical applicator resulted in tumour necrosis up to 8 mm in depth. In larger tumours a rim of viable tumour was observed on the side opposite to illumination. In a randomised study, survival of treated animals was significantly longer than in the untreated control group (log-rank-test, P <0.02), although all animals died of recurrent tumour. This technique shows promise in the treatment of small volumes of tumour in the pancreas.
Pancreatic cancer has one of the poorest prognoses of any cancer. Most patients die within 6 months of diagnosis. The 1 and 5 year survival rates are about 10% and 1-2% respectively. It is one of the most common cancers of the gastrointestinal tract, and its incidence is increasing. Radical surgery is rarely possible, and radiotherapy and chemotherapy are of no proven benefit. Photodynamic therapy (PDT) is a new and promising approach to therapy for tumours. It is a non-thermal technique for producing localised tissue necrosis with light-activated photosensitising compounds. Systemic administration of the photosensitiser is followed by exposure to laser light at a wavelength matched to an absorption peak of the sensitiser, resulting in the generation of cytotoxic singlet oxygen. Ideally, the photosensitiser should be selectively retained in the tumour and not in the surrounding normal tissue. This would ensure safe destruction of the tumour within normal areas. However, even if there is some selectivity in the tumour uptake of the photosensitiser, truly selective destruction is difficult to obtain and therefore some degree of normal tissue damage has to be accepted provided safe healing can occur (Bown, 1990) . Haematoporphyrin derivative (HpD) and its purer commercial variants (e.g. Photofrin) are the most commonly used photosensitisers in clinical practice. They are both rather poorly defined mixtures of porphyrins and have the clinically important disadvantage of causing prolonged skin photosensitivity lasting for about 4-6 weeks (Dougherty et al., 1990) .
Pancreatic cancer has never been treated by PDT in humans, but experim6ntal studies on pancreatic tumour models in hamsters or rats have been carried out (Mang & Wieman, 1987; Schroder et al., 1988; Chatlani et al., 1992) . The common conclusions drawn from those studies are encouraging. Necrosis of the pancreatic cancer was achieved easily and, more importantly, normal pancreatic tissue surrounding the tumour showed resistance to PDT damage (Mang & Wieman, 1987; Nuutinen et al., 1991; Chatlani et al., 1992 (Bedwell et al., 1992; Peng et al., 1992) and also after topical application of ALA for 300 cutaneous basal cell carcinoma lesions in Canada (Kennedy & Pottier, 1992) and in oral cancer patients following systemic ALA administration (Grant et al., 1993) . The main advantages of using ALA as a photosensitising agent lie in the rapid elimination of ALA from the body, short-lived photosensitisation lasting not longer than 24 h and the possibility of oral administration, which is more acceptable and easier than any parenteral route (Berlin et al., 1956; Mustajoki et al., 1992; Grant et al., 1993; Loh et al., 1993a (Bedwell et al., 1992 (Loh et al., 1993a,b) touching the surface of the tumour to deliver the chosen energy of 50 J (50 mW for 1,000 s); in method 2 we used a 400 gAm microlens fibre mounted inside a light-integrating cylinder with a reflective inner surface (2.5 cm long, fibre position 2 cm above the area to be irradiated), which enabled more selective tumour illumination with a surface irradiance of 50 J cm-2 (100 mW cm-2 for 500 s). Animals were killed 3, 5, 6 or 7 days later and, at autopsy, damage to the tumour and surrounding normal tissues was assessed macroscopically and relevant samples collected for histological analysis.
Survival study Twenty hamsters weighing 110 g (± 10 g) were injected with PC-I cells as described above with the intention of performing a control laparotomy for tumour assessment 3 weeks later. One animal had to be killed the day after PC-I injection because of an incisional hernia. Of the remaining 19 animals, control laparotomy performed 20-22 days after tumour implantation revealed that four had no tumour and that two had developed liver metastases and so these six animals were excluded from the survival study. All animals, including those from the control group, received the first oral fractionated dose of ALA 5 h before laparotomy and randomisation. Only animals with suitable tumours were randomised. Hence, 13 tumour-bearing hamsters were randomised to either the treatment or control group according to our code, allowing for about twice as many animals in the active treatment group. As a result of randomisation, nine hamsters with a mean ( standard deviation) tumour diameter of 1.4 (± 0.6 cm) underwent treatment with irradiation method 2 described above, and four hamsters with a mean tumour diameter of 1.3 ± 0.5 cm formed the control, untreated group. The tumour diameters in the two groups did not differ statistically (Mann-Whitney U-test, P = 0.81). Method 2 was chosen for light exposure because we thought that shielding of the normal tissues was desirable in the long-term survival study. The oral fractionated dosage was chosen because the intravenous method required two laparotomies on the treatment day and the oral bolus dose gave weaker fluorescence in the tumour than the fractionated one. After laparotomy and wound repair, animals were allowed to recover and then observed every 2 days. Survival time was defined as the time from the control laparotomy (with or without laser treatment) to death. All animals underwent necropsy examination. Six hamsters from the treated group and two from the control group were killed when they became distressed because of carcinomatosas (respiratory failure with ascites). Care was taken to apply the same criteria of distress in all aimals. These studies were carried out in accordance with procedures approved by the Home Office.
Statistical analysis
Fluorescence intensity at a given time point was expressed as a mean of measurements obtained from 2-4 animals after subtracting autofluoescence intensity obtained from the same tissues in non-sensitised animals. Each animal had fluorescene measured in the tumour and normal pancreas at two sites in at least two frozen sections. For survival analysis Kaplan-Meier curves were created and survival probabilities compared with the log-rank test. A difference was considered to be significant at a P-value less than 0.05. 
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counts per pixel at 4 h. The peak time point was similar for an oral bolus dose (at 4 h), but the fluorescence intensity was only half the level of that after i.v., despite the higher dose given. Oral fractionated dosage gave fluorescence levels lower than after i.v. but higher than after o.b. administration. Peak values were detected at 5 h after the first dose, i.e. 1 h after the last fractionated dose. An example of a fluorescence image from tumour and adjacent normal pancreas at the 5 h time-point is shown in Figure 2 , which demonstrates the marked tumour selectivity in fluorescence levels. Table I gives the values and times of maximum tumour fluorescence for each administration route together with the corresponding fluorescence ratio between tumour and normal pancreas.
Photodynamic therapy-short -term results
The earliest results were obtained 3 days and the latest 7 days after treatment. In all treated tumours (n = 13) necrosis was evident, and the largst necrotic area had a diameter of 0.8 cm. Progression of the necrotic changes could be seen on serial slides obtained on days 3, 5, 6 and 7. On day 3 the 'skeleton of the tumour' (i.e. damaged but recognisable histological structure of the tumour) could still be seen, but on day 7 mostly just amorphous necrotic material was present. Smaller tumours showed complete necrosis of the entire lesion, but larger ones usually had a rim of viable tumour on the side opposite the irradiated surface (Figure 3) . The distance from the irradiated surface of the tumour to the viable tdmour rim was up to 0.8 cm. The border between necrosed and viable tumour was uneven and had a tendency to follow the lobular structure of the tumour delineated by thin connective tissue 'strips' (Figure 4 ), which may be related to the vascular supply to the different parts of the tumour or to the protective role of connective tissue strips. The extent of the tumour necrosis did not depend on the method of irradiation and was similar for methods I and 2.
Normal pancreatic tissue present at the borders of the tumour and surrounding it in most of the sections was not damaged. However, usually small areas of pancreatic oedema or even necrosis could be detected, but only in places where direct irradiation took place. Control animals with untreated tumour killed 28 days after tumour implantation (similar time of observation as the longest observation period in the treated group, namely 7 days after treatment) exhibited only small areas of spontaneous tumour necrosis located in the middle part of the tumour, which was in marked contrast to the location of the PDT necrosis, which extended from the borders of the tumour.
Survival study
The mean survival time of control untreated animals was 42 days (range 29-51). Animals treated with PDT after an oral fractionated dose of ALA (400 mg kg-') irradiated at 5 h with the cylindnrcal applicator (50 J cm-2) survived significantly longer according to the Kaplan-Meier analysis of survival curves (log-rank test; x = 5.86, P<0.02) ( Figure  5) animals from the treated group. In particular, there was no evidence that laser treatment had caused any stenosis or perforation of the stomach, duodenum or biliary tree.
There are only three published studies addressing PDT treatment of experimental pancreatic cancer. However, the methods used to induce the tumour in these studies were different from our model. In the first study two models were employed (Mang & Wieman, 1987 (Mang & Wieman, 1987; Schroeder et al., 1988) Photofrin was used as the photosensitising agent, whilst Chatlani et al. (1992) studied aluminium sulphonated phthalocyanine (AlSPc). The alluring feature of 5-aminolaevulinic acid (ALA)-induced PPIX sensitisation, as used in this study, is-the significantly decreased risk of prolonged skin photosensitivity. ALA can also be administered orally, as has been reported in human subjects, but only as a Fuge 5 Kaplan-Meier survival curves for Syrian golden hamsters with transplanted pancreatic tumours companing the PDTtreated group (-= 9) with the control, non-treated group (0, n=4) (log-rank test, P<0.02).
single bolus dose (Berlin et al., 1956; Grant et al., 1993; Loh et al., 1993a) . We have compared two methods of oral ALA administration (bolus and fractionated). We anticipated that oral fractionated doses would result in better tissue uptake than an oral bolus because ALA and its metabolite, porphobilinogen, are very quickly excreted in the urine after a bolus dose (Berlin et al., 1956) . The peak plasma concentration of ALA in humans after a single dose is reached at 60 min and the half-life (t,2) of its clearance from the circulation is only about 50 min (Mustajoki et al., 1992) , so frequent repeated doses should maintain a steady, high blood level of ALA for a longer time. A similar approach was adopted in another recent study in which prolonged administration of ALA to rats over 11 days (in drinking water) resulted in a better liver tumour/normal liver PPIX ratio than shorter periods of administration (van Hillegersberg et al., 1992) . This tendency for better tumour uptake of ALA and accumulation of PPIX after fractionated as opposed to bolus dosing was confirmed in the present study. Another potential advantage of fractionating the ALA dose is that any asynchrony in PPIX synthesis among the malignant cells may be minimised. However, in this work the best results in terms of the efficiency of PPIX conversion from ALA were obtained after intravenous injection, as found previously in studies of normal rat stomach and colon (Loh et al., 1993a) . ALA arriving from the portal circulation after an oral dose can be quickly metabolised to porphyrins by hepatocytes in situ and then excreted into the bile and thus lost to the systemic circulation. Recent studies of animal tissues after systemic ALA administration using chemical extraction have shown that the porphyrin content is at least 95% protoporphyrin IX (Loh et al., 1993b) . Good correlation was also found between chemically extracted levels of PPIX and microfluorimetric measurements using our technique in tissue layers of the gastrointestinal tract (Loh et al., 1993b Loh et al. (1993a) . The ratio between tumour and normal pancreatic tissue fluorescence levels in our study varied at different time points beween 1: 1 and 8:1. For intravenous and oral (fractionated) administration the selectivity ratio between tumour and pancreas at the time of maximum tumour fluorescence was 5-6:1, although with oral (bolus) administration this ratio was lower at 3:1. However Mang and Wieman (1987) found no difference in Photofrin concentrations 24 h after injection between intrapancreatic tumours and normal pancreas in their rat and hamster models. In the study of Schroeder et al. (1988) the activity of '"I-labelled Photofrin was studied 3 and 48 h after administration and was almost twice as high in the pancreatic tumour as in the normal pancreas at both time points. In the case of aluminium sulphonated phthalocyanine (a mixture containing mono-to tetrasulphonates with the mean corresponding to trisulphonated) at the optimum time (48 h), the chemically extracted concentration (as measured using fluorescence detection) was about three times higher in the pancreatic tumours as in the normal pancreas (Chatlani et al., 1992) . Hence, using ALA-induced PPIX sensitisation the tumour to normal ratios demonstrate better selectivity than found with conventional exogenous sensitisation. Good selectivity has also been found in large bowel and experimental mammary carcinomas with this method of sensitisation (Bedwell et al., 1992; Peng et al., 1992) . One of the possible explanations for this selective tumour accumulation of PPIX could be lower ferrochelatase activity in the tumour cells compared with normal tissues, as shown by van Hillegersberg (1992) and Schoenfeld et al. (1988) in combination with higher levels of porphobilinogen deaminase in tumour (BatlIe. 1993). However, the selectivity found here is exceptional and must partly be explained by the relatively low PPIX fluorescence levels found in normal pancreas, which may also be a consequence of low activities of certain haem enzymes in this organ. On reaching maximum fluorescence levels in the pancreas, the PPIX appears to be associated with intercellular regions corresponding to the capillary and lymphatic network. A similar fluorescence pattern has been noted for the porphyrins and phthalocyanines (Nuutinen et al., 1991) .
Further work with confocal imaging to give higher resolution would be desirable and might help to explain the resistance of normal pancreas to PDT damage, which appears to be a general phenomenon applying to all sensitisers studied thus far. When the same light dose was applied to the tumours and normal pancreas in the experiments of Mang and Wieman (1987) (tumour and normal pancreas had identical Photofrin concentrations), the damage was limited to tumour only. This phenomenon was accompanied by a notable lack of photobleaching of the Photofrin in normal tissues as compared with photobleaching in the tumour. It was suggested that normal pancreas contains high amounts of singlet oxygen scavengers which could maintain sublethal levels of singlet oxygen and also inhibit singlet oxygen-induced photodegradation. Chatlani et al. (1992) reported results with sulphonated aluminium phthalocyanine showing that the light dose necessary to induce necrosis in tumours resulted in no damage to normal pancreas. These authors also calculated that the threshold photodynamic dose for damage (light dose multiplied by concentration of photosensitiser) to normal pancreas was about seven times as high as for damage to pancreatic tumour. Studies trying to explain this phenomenon have been undertaken but are inconclusive (Matthew & Cui, 1990; Moesta et al., 1992) . Studies of photobleaching of ALA-induced PPIX and phthalocyanine in pancreas would provide a useful comparison with those performed with Photofrin. On the other hand, serious pancreatic damage was induced in another study (Schroder et al., 1988) in which irradiation of the tumour was performed from a distance of about 3-4 cm, and most probably larger areas of normal pancreas and other organs around were irradiated. This caused necrotising pancreatitis and death in one of seven animals. Another three animals also died from gastroduodenal perforations. The irradiation techniques described in the present study limited exposure to the pancreatic tumour and small areas of adjacent normal pancreas. Using this method only small areas of damage to the normal pancreas could be seen on histological examination, and these were at the places directly exposed to laser light. One cannot exclude the possibility that this was a result of thermal damage, which all PDT studies try to exclude. Many previous studies have reported small areas of damage where the fibre touches the target -so-called thermal controls (exposed to laser without previous sensitiser administration) (Barr et al., 1987; Chatlani et al., 1992) .
The maximum depth of necrosis induced in the tumours by PDT in our study was 8 mm, with a viable rim of undamaged tumour tissue at the side opposite the irradiated area. Borders between necrotic areas and viable tumour appeared to follow the lobular structure of the tumour. This may be related to the vascular supply pattern of the tumour or perhaps the protective role of connective tissue strips dividing tumour into lobules. Of the three experimental pancreatic tumour PDT studies, only Chatlani et al. (1992) give a description of the localisation of the necrosis within the tumour. Their description is quite similar to our findings. They also reported a maximum of 8 mm necrosis of the tumour and a viable rim at the areas furthest from the site of light application. One can argue that the presence of a viable tumour rim should be considered an unsatisfactory result, but it is well established that light penetration is a limiting factor of PDT. If surface illumination, as used in our study, can produce damage up to 8 mm, this would be sufficient if PDT followed other tumour volume-reducing procedures such as surgery, and in these circumstances PDT would only aim at 'sterilising' resection margins. Other possibilities can also be considered, such as multiple fibres inserted at different depths into the tumour tissue to illuminate larger volumes.
No other studies have presented survival analysis after PDT for pancreatic tumours. This study shows favourable results, with significant prolongation of survival after treatment. However, all animals had a tumour recurrence, most probably from the rims of viable tumour observed in our short-term study or from incompletely destroyed microscopic foci of tumour.
In summary, the results of this study suggest that pancreatic tumours up to 8 mm in depth can be destroyed following ALA administration and application of 50 J cm-2 of 630 nm laser light. Partial destruction of the tumour results in a prolongation of survival of experimental animals. These data would justify further studies of PDT for pancreatic cancer, which should also consider how pancreatic tumours could be treated in clinical practice. Imaging of pancreatic lesions is difficult and leads to delays in diagnosis and treatment. Therefore the most probable application of PDT in this disease would be as an adjunct to surgery. In this situation destruction of tumour to a depth of up to 8 mm, as found here, can be sufficient to destroy micrometastases in the operative area, and for small tumours PDT could be used as the primary treatment. Intraoperative PDT is already being seriously considered (DeLaney et al., 1993; Evrad et al., 1993 ) and hopefully will become established in the future treatment of intra-abdominal malignancy.
